Another week, another review, or even reviews. The latest HTA Review announcement confirmed new review processes on discount rates, comparators, and co-dependent pathways, which have all been repeatedly examined over the past decade. These endless bureaucratic reviews are about squeezing the life out of actual reform, like juice from a lemon. Meanwhile, patients keep paying the price for this Faustian pact, and for some, that means dying.
Latest Video
New Stories
-
Australian dementia experts push back on Cochrane Review, defending new treatments
April 20, 2026 - - Latest News -
Australia’s drug pricing dogma risks failing patients in the face of international realities
April 20, 2026 - - Latest News -
Free RSV vaccines roll out to protect senior Australians ahead of winter
April 20, 2026 - - Latest News -
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News
